USA-based biopharmaceutical company Dynavax Technologies says that data from a preclinical assessment of an influenza vaccine it is developing, indicates that it confers immunity to "widely divergent" strains of the virus. The firm said that analysis of the agent in animal models suggests that it has the potential to become a universal influenza vaccine.
The firm added that co-administration of its product and a standard flu vaccine enhances the immune response, and may lower the dose of the standard treatment that is required to induce protective immunity.
Dynavax explained that it is trying to develop an agent with a greater therapeutic scope than the current pandemic-driven research efforts undertaken by other firms. In 2003, the company received a $3.0 million grant from the US National Institute of Allergy and Infectious Disease, funding the research and development of its Toll Like Receptor-9 technology-based flu vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze